"Neoadjuvant Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.
| Descriptor ID |
D020360
|
| MeSH Number(s) |
E02.186.450
|
| Concept/Terms |
Neoadjuvant Therapy- Neoadjuvant Therapy
- Neoadjuvant Therapies
- Therapies, Neoadjuvant
- Therapy, Neoadjuvant
- Neoadjuvant Treatment
- Neoadjuvant Treatments
- Treatment, Neoadjuvant
- Treatments, Neoadjuvant
|
Below are MeSH descriptors whose meaning is more general than "Neoadjuvant Therapy".
Below are MeSH descriptors whose meaning is more specific than "Neoadjuvant Therapy".
This graph shows the total number of publications written about "Neoadjuvant Therapy" by people in this website by year, and whether "Neoadjuvant Therapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 1 | 1 | 2 |
| 2005 | 3 | 3 | 6 |
| 2006 | 1 | 7 | 8 |
| 2007 | 2 | 3 | 5 |
| 2008 | 3 | 2 | 5 |
| 2009 | 0 | 3 | 3 |
| 2010 | 0 | 5 | 5 |
| 2011 | 1 | 6 | 7 |
| 2012 | 3 | 3 | 6 |
| 2013 | 4 | 7 | 11 |
| 2014 | 1 | 6 | 7 |
| 2015 | 3 | 7 | 10 |
| 2016 | 1 | 10 | 11 |
| 2017 | 5 | 9 | 14 |
| 2018 | 4 | 7 | 11 |
| 2019 | 9 | 9 | 18 |
| 2020 | 3 | 11 | 14 |
| 2021 | 5 | 11 | 16 |
| 2022 | 3 | 10 | 13 |
| 2023 | 3 | 16 | 19 |
| 2024 | 10 | 5 | 15 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoadjuvant Therapy" by people in Profiles.
-
Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial. Nat Med. 2025 Jan; 31(1):144-151.
-
Combining Biology-based and MRI Data-driven Modeling to Predict Response to Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Radiol Artif Intell. 2025 Jan; 7(1):e240124.
-
Circulating Tumor DNA as a Prognostic Biomarker for Recurrence in Patients With Locoregional Esophagogastric Cancers With a Pathologic Complete Response. JCO Precis Oncol. 2024 Dec; 8:e2400288.
-
Estrogen Signaling in Early-Stage Breast Cancer: Impact on Neoadjuvant Chemotherapy and Immunotherapy. Cancer Treat Rev. 2025 Jan; 132:102852.
-
Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial. Nat Med. 2025 Jan; 31(1):176-188.
-
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer. Cell Rep Med. 2024 Nov 19; 5(11):101799.
-
DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial. JCO Precis Oncol. 2024 Nov; 8:e2400287.
-
Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status?. ESMO Open. 2024 Nov; 9(11):103973.
-
Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy in High-Grade Epithelial Ovarian Cancer: A LANCE Randomized Clinical Trial. JAMA Netw Open. 2024 Nov 04; 7(11):e2446325.
-
Heterogeneity of Residual Disease After Neoadjuvant Systemic Therapy in Breast Cancer: A Review. JAMA Oncol. 2024 Nov 01; 10(11):1578-1584.